Eosinophilic esophagitis during peanut oral immunotherapy with omalizumab

Ítems similars

• Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy
  per: Vickery, Brian P., et al.
  Publicat: (2013)
• Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy
  per: Burk, Caitlin M., et al.
  Publicat: (2016)
• Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective
  per: Vickery, Brian P., et al.
  Publicat: (2016)
• Novel Baseline Predictors of Allergic Side Effects During Peanut Oral Immunotherapy
  per: Virkud, Yamini V., et al.
  Publicat: (2016)
• Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children
  per: Thyagarajan, Ananth, et al.
  Publicat: (2012)